Soleno Therapeutics' (SLNO) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Soleno Therapeutics (NASDAQ:SLNO – Get Rating) in a report published on Friday, Benzinga reports. Oppenheimer currently has a $8.00 target price on the stock. Oppenheimer also issued estimates for Soleno Therapeutics’ FY2027 earnings at $4.09 EPS. Soleno Therapeutics Stock Performance Shares of Soleno Therapeutics stock opened at […]

Related Keywords

,Soleno Therapeutics Inc ,Millennium Management ,Renaissance Technologies ,Clayton Partners ,Worth Venture Partners ,Soleno Therapeutics Company Profile ,Soleno Therapeutics ,Get Rating ,Soleno Therapeutic ,Diazoxide Choline Controlled Release ,Prader Willi Syndrome ,Soleno Therapeutics Daily ,Nasdaq Slno ,Slno ,Medical ,Reiterated Rating ,Oppenheimer Holdings Inc ,